Kodiak Sciences (KOD) Form 4 Filings

Kodiak Sciences Inc. director Taiyin Yang exercised 20,000 stock options on October 23, 2026, acquiring 20,000 common shares at an exercise price of $2.35 per share. The options were fully vested and had an expiration date of June 28, 2034. Yang reported direct ownership of 20,000 common shares following the transaction. No Rule 10b5-1 plan is reported.

Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson exercised options for 30,000 common shares on October 21, 2026, at an exercise price of $2.49 per share, and sold 30,000 shares that day. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2025. The eight reported sale entries show prices from $87.67 to $94.91 per share; footnotes describe weighted-average prices for the entries they cover. The option row reports 304,500 underlying shares following the exercise and an expiration date of August 4, 2034.

Kodiak Sciences Inc. (KOD) reports indirect purchases of 715,592 common shares by 667, L.P. and Baker Brothers Life Sciences LP on September 28 and 29, 2026, at reported weighted-average prices of $84.2421 to $89.8555 per share. No Rule 10b5-1 plan is reported. Baker Bros. Advisors LP, the funds’ investment adviser, had complete and unlimited discretion and authority over investment and voting power. Directors Felix J. Baker and Julian C. Baker may be deemed to have indirect pecuniary interests through their fund interests and profit allocations.

Kodiak Sciences Inc. (KOD) reports that 667, L.P. and Baker Brothers Life Sciences, L.P. purchased 418,323 common shares on September 28, 2026, at reported weighted-average prices ranging from $79.4045 to $85.9656 per share. Julian C. Baker and Felix J. Baker, managing members of Baker Bros. Advisors (GP) LLC, may be deemed to have indirect pecuniary interests in shares held by the funds; they disclaim beneficial ownership except to the extent of those interests. No Rule 10b5-1 plan is reported.

Kodiak Sciences Inc. (KOD) shares were purchased by 667, L.P. and Baker Brothers Life Sciences, L.P., which bought 807,840 common shares on September 28, 2026, through multiple transactions. The listed weighted-average prices ranged from $61.2104 to $78.5681 per share. No Rule 10b5-1 plan is reported.

Kodiak Sciences Inc. Chairman and CEO Victor Perlroth exercised stock options on September 25, 2026, to acquire 1,280,524 common shares. The options covered 600,000 shares at a $5.38 exercise price, 365,840 shares at $2.49, and 314,684 shares at $3.95 per share.

Kodiak Sciences Inc. reported a compensation grant to Chief Financial Officer John A. Borgeson of stock options covering 66,500 shares of common stock on July 15, 2026. The options have an exercise price of $42.42 per share, expire on July 14, 2036, and were fully unvested at grant. One-forty-eighth of the shares vest one month after July 1, 2026, with the remaining shares vesting in forty-seven equal monthly installments thereafter, subject to his Continuous Service under the 2018 Equity Incentive Plan.

Kodiak Sciences Inc. reported that Chairman, CEO and 10% owner Victor Perlroth received a grant of stock options covering 100,000.0000 shares of Common Stock at an exercise price of $42.4200 per share. These options expire on 2036-07-14 and vest monthly beginning after July 1, 2026, subject to his Continuous Service.

Kodiak Sciences Inc. director Yang Taiyin received a new stock option grant as part of equity compensation. The award covers 17,731 stock options for common stock at an exercise price of $38.96 per share, with no cash paid at grant.

All 17,731 options will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Yang continues serving on the board through the applicable vesting date. Following this grant, Yang holds 17,731 stock options directly.

Kodiak Sciences Inc. director Robert Profusek received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.

All 17,731 option shares vest in full on the earlier of June 30, 2027 or one day before the company’s next annual meeting after the grant date, as long as he continues serving on the board through that vesting date. Following this grant, he holds 17,731 derivative securities directly.

Kodiak Sciences Inc. director Richard S. Levy received a stock option grant covering 17,731 shares of common stock. The option has an exercise price of $38.96 per share and expires on June 29, 2036. Following this grant, he holds options for 17,731 shares directly.

All 17,731 option shares will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Levy continues to serve on the board of directors through the applicable vesting date.

Kodiak Sciences Inc. director Bassil I. Dahiyat received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.

All 17,731 option shares vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak’s next annual shareholder meeting after the grant date, provided Dahiyat continues to serve on the board through that vesting date.

Kodiak Sciences director Charles A. Bancroft received a new stock option grant, giving him the right to buy 17,731 shares of common stock at an exercise price of $38.96 per share. These options were granted at no cost to him on June 30, 2026.

The entire option grant vests in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, as long as Bancroft continues to serve on the company’s board of directors through that vesting date. After this grant, he holds options for 17,731 shares directly.

BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.

Kodiak Sciences Inc. reported a compensation-related insider transaction involving a grant of non-qualified stock options linked to entities associated with Julian and Felix Baker. On June 30, 2026, Felix J. Baker, serving as a director, received a grant of 17,731 stock options exercisable into Kodiak common stock at a strike price of $38.96 per share under the company’s 2018 Equity Incentive Plan. The options vest on the earlier of the first anniversary of the grant or one day before the next annual stockholder meeting, provided he continues serving on the board, and they expire on June 29, 2036. The grant is reported for multiple Baker-affiliated funds because each has an indirect proportionate pecuniary interest, while Baker Bros. Advisors LP holds voting and dispositive power and the Baker parties and the adviser disclaim beneficial ownership beyond their economic interest.

Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction in company stock. He exercised stock options for 30,000 shares of common stock at an exercise price of $1.04 per share and acquired those shares. On the same date, he sold a total of 30,000 shares of common stock in open-market transactions at weighted-average prices of $34.01 and $34.67 per share, as disclosed in two sale entries. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly holds 211,930 shares of Kodiak Sciences common stock.

Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson exercised stock options to acquire 28,614 shares of common stock at an exercise price of $1.04 per share. Following the transaction, he directly owns 211,930 common shares and holds options for 30,000 additional shares. The options exercised were already fully vested, indicating this was a routine compensation-related exercise rather than an open-market purchase or sale.

Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction involving company stock. On April 2, 2026, he exercised stock options to acquire 30,000 shares of Common Stock at an exercise price of $1.04 per share. The option was fully vested and scheduled to expire on June 22, 2026.

On the same date, he sold a total of 30,000 Common shares in multiple open-market transactions at weighted-average prices of $39.14, $40.29, $40.88, and $41.77 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, Borgeson directly holds 183,316 shares of Kodiak Sciences Common Stock.

Kodiak Sciences Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise. Following the transaction, he directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this filing, and the derivative position tied to this specific option grant has been fully converted into common shares.

Kodiak Sciences Inc. reported that Chairman and CEO Victor Perlroth received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $25.0000 per share and expire on March 17, 2036.

The award is performance-based. Vesting will be determined by the 30-day average stock price as of June 30, 2027, defined as the Performance Criteria Achievement Date. If the average price is less than $25.00, none of the options vest; at or above $25.00, one-third vests; above $30.00, two-thirds vests; and above $35.00, all 175,000 options vest, subject to Perlroth continuing as a service provider on that date.